11C-acetate PET for early prediction of sunitinib response in metastatic renal cell carcinoma

Alessandra Maleddu1, Maria A Pantaleo1, Paolo Castellucci2, Maria Astorino1, Cristina Nanni2, Margherita Nannini1, Fiorenza Busato3, Monica Di Battista1, Mohsen Farsad2, Filippo Lodi1, Stefano Boschi1, Stefano Fant1, and Guido Biasco1

1Institute of Hematology and Medical Oncology “L. & A. Seragnoli”, 2Nuclear Medicine Service, 3Malpighi Radiology Unit, Department of Digestive Diseases and Internal Medicine, and 4PET Radiopharmacy Nuclear Medicine Service, Sant’Orsola-Malpighi Hospital, University of Bologna, Bologna, Italy

ABSTRACT

Sunitinib is an oral multtargeted tyrosine kinase inhibitor with antiangiogenic properties used for treatment of renal cell carcinoma and gastrointestinal stromal tumors at a dose of 50 mg/day consecutively for 4 weeks followed by 2 weeks off per cycle. At present, no data are available on the early prediction of sunitinib response in renal cell carcinoma. We report a clinical case of a patient with metastatic renal cell carcinoma diagnosed with 11C-acetate PET and conventional CT and treated with sunitinib. Partial and complete remission documented by CT was preceded by early functional tumor inhibition shown by 11C-acetate-PET after only 14 days of therapy. This case report highlights some interesting points related to the potential role of a novel non-FDG PET tracer, 11C-acetate, in the early prediction of the response to targeted therapies in metastatic renal cell carcinoma.

Key words: PET, sunitinib, renal cell carcinoma, treatment response prediction.

Correspondence to: Alessandra Maleddu, MD, University of Bologna, Institute of Hematology and Medical Oncology “L. & A. Seragnoli”, Sant’Orsola-Malpighi Hospital, Via Massarenti 9, 40138 Bologna, Italy. Tel + 39-051-6364078; fax + 39-051-6364037; e-mail alessandramaleddu@gmail.com

Received June 4, 2008; accepted September 9, 2008.